



If a conflict arises between a Clinical Payment and Coding Policy (“CPCP”) and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. “Plan documents” include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. BCBSNM may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSNM has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act (“HIPAA”) approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing (“UB”) Editor, American Medical Association (“AMA”), Current Procedural Terminology (“CPT®”), CPT® Assistant, Healthcare Common Procedure Coding System (“HCPCS”), ICD-10 CM and PCS, National Drug Codes (“NDC”), Diagnosis Related Group (“DRG”) guidelines, Centers for Medicare and Medicaid Services (“CMS”) National Correct Coding Initiative (“NCCI”) Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

ZIKA Virus Risk Assessment

Policy Number: CPCPLAB042

Version 1.0

Enterprise Medical Policy Committee Approval Date: 1/25/2022

Plan Effective Date: May 1, 2022

Description

BCBSNM has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

1. Zika virus urine, serum, and CSF RNA NAT testing and IgM testing in infants **may be reimbursable** in the following situations:
 - a. infants with clinical findings consistent with congenital Zika syndrome and possible maternal Zika virus exposure during pregnancy, regardless of maternal testing results

- b. infants without clinical findings consistent with congenital Zika syndrome born to mothers with laboratory evidence of possible Zika virus infection during pregnancy
- 2. Zika virus RNA NAT testing of amniocentesis, placental and fetal tissues **may be reimbursable** in pregnant women with possible exposure to Zika virus and who have a fetus with prenatal ultrasound findings consistent with congenital Zika virus infection and undergoing amniocentesis.
- 3. Zika virus urine and serum RNA NAT testing and Zika virus serum IgM testing **is not reimbursable** for the following:
 - a. Symptomatic, nonpregnant individuals;
 - b. Asymptomatic individuals, including asymptomatic pregnant individuals; OR
 - c. For preconception screening
- 4. Zika virus urine and serum RNA NAT testing **is not reimbursable** in all symptomatic non-pregnant individuals presenting with ≥ 14 days after symptoms onset.
- 5. Zika virus serum IgM testing **is not reimbursable** in symptomatic pregnant women.
- 6. All other tests for diagnosing Zika virus not mentioned above in all other situations and testing of samples other than serum, urine, CSF, amniocentesis, placental and fetal tissues at this time **is not reimbursable**.

Procedure Codes

Codes
86794, 87662

References:

AAP. (2018). Report of the Committee of Infectious Diseases “Red Book”

ACOG. (2017). Practice Advisory Interim Guidance for Care of Obstetric Patients During a Zika Virus Outbreak. Retrieved from <https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Interim-Guidance-for-Care-of-Obstetric-Patients-During-a-Zika-Virus-Outbreak>

ACOG. (2019). Management of Patients in the Context of Zika Virus: ACOG COMMITTEE OPINION SUMMARY, Number 784. *Obstet Gynecol*, 134(3), 655-657. doi:10.1097/aog.0000000000003400

ASM. (2016, May 10). Zika Virus: An Update on the Disease and Guidance for Laboratory Testing. Retrieved from <https://asm.org/Guideline/Zika-virus-An-update-on-the-disease-and-guidance-f>

Basu, R., & Tumban, E. (2016). Zika Virus on a Spreading Spree: what we now know that was unknown in the 1950's. *Virology*, 13(1), 165. doi:10.1186/s12985-016-0623-2

CATMAT. (2019). Zika Virus Prevention and Treatment Recommendations. Retrieved from <https://www.canada.ca/en/public-health/services/publications/diseases-conditions/zika-virus->

prevention-treatment-recommendations.html

CATMAT. (2020). Zika Virus Prevention and Treatment Recommendations. Retrieved from <https://www.canada.ca/en/public-health/services/publications/diseases-conditions/zika-virus-prevention-treatment-recommendations.html>

CDC. (2016). Overview. Retrieved from <https://www.cdc.gov/zika/about/overview.html>

CDC. (2017a). Guidance for US Laboratories Testing for Zika Virus Infection. Retrieved from <https://www.cdc.gov/zika/laboratories/lab-guidance.html>

CDC. (2017b). Trioplex Real-time RT-PCR Assay Retrieved from <https://www.cdc.gov/zika/pdfs/trioplex-real-time-rt-pcr-assay-instructions-for-use.pdf>

CDC. (2017c). Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection — United States, October 2017 | MMWR. @cdcmmwr Retrieved from <https://www.cdc.gov/mmwr/volumes/66/wr/mm6641a1.htm>

CDC. (2019a). Testing Guidance. Retrieved from <https://www.cdc.gov/zika/hc-providers/testing-guidance.html>

CDC. (2019b). Types of Zika Virus Tests. Retrieved from <https://www.cdc.gov/zika/laboratories/types-of-tests.html>

Co-Diagnostics. (2018). Logix Smart Zika Virus (ZIKV) Test™. Retrieved from http://codiagnostics.com/wp-content/uploads/2018/10/Instructions-for-Use-Logix-Smart-ZIKV-004-Test-Kit-Rev_5.pdf

FDA. (2017). cobas® Zika. Retrieved from <https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM579310.pdf>

FDA. (2018). Procleix Zika Virus Assay Retrieved from <https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM612710.pdf>

Granger, D., Hilgart, H., Misner, L., Christensen, J., Bistodeau, S., Palm, J., . . . Theel, E. S. (2017). Serologic Testing for Zika Virus: Comparison of Three Zika Virus IgM-Screening Enzyme-Linked Immunosorbent Assays and Initial Laboratory Experiences. *J Clin Microbiol*, 55(7), 2127-2136. doi:10.1128/jcm.00580-17

Granger, D., & Theel, E. S. (2019). Evaluation of a Rapid Immunochromatographic Assay and Two Enzyme-Linked Immunosorbent Assays for Detection of IgM-Class Antibodies to Zika Virus. *J Clin Microbiol*, 57(3). doi:10.1128/jcm.01413-18

Kim, Y. H., Lee, J., Kim, Y.-E., Chong, C.-K., Pinchemel, Y., Reisdörfer, F., . . . Nam, H.-W. (2018). Development of a Rapid Diagnostic Test Kit to Detect IgG/IgM Antibody against Zika Virus Using Monoclonal Antibodies to the Envelope and Non-structural Protein 1 of the Virus. *The Korean journal of parasitology*, 56(1), 61-70. doi:10.3347/kjp.2018.56.1.61

LeBeaud, A. D. (2021, February 22). Zika virus infection: An overview. Retrieved from

<https://www.uptodate.com/contents/zika-virus-infection-an-overview>

Li, S., Zhao, H., Yang, H., Hou, W., Cruz-Cosme, R., Cao, R., . . . Cheng, T. (2019). Rapid Neutralization Testing System for Zika Virus Based on an Enzyme-Linked Immunospot Assay. *ACS Infect Dis.* doi:10.1021/acsinfecdis.9b00333

Lin, K. W., Kraemer, J. D., Piltch-Loeb, R., & Stoto, M. A. (2018). The Complex Interpretation and Management of Zika Virus Test Results. *J Am Board Fam Med*, 31(6), 924-930. doi:10.3122/jabfm.2018.06.180061

Maternova. (2019). Zika Rapid Test. Retrieved from <https://maternova.net/products/zika-rapid-test>

Moore, C. A., Staples, J. E., Dobyns, W. B., Pessoa, A., Ventura, C. V., Fonseca, E. B., . . . Rasmussen, S. A. (2017). Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians. *JAMA Pediatr*, 171(3), 288-295. doi:10.1001/jamapediatrics.2016.3982

Nielsen-Saines, K. (2019, November 25). Congenital Zika virus infection: Clinical features, evaluation, and management of the neonate. Retrieved from <https://www.uptodate.com/contents/congenital-zika-virus-infection-clinical-features-evaluation-and-management-of-the-neonate>

Papageorghiou, A. T., Thilaganathan, B., Bilardo, C. M., Ngu, A., Malinger, G., Herrera, M., . . . Copel, J. A. (2016). ISUOG Interim Guidance on ultrasound for Zika virus infection in pregnancy: information for healthcare professionals. *Ultrasound Obstet Gynecol*, 47(4), 530-532. doi:10.1002/uog.15896

Petersen, L. (2018). Clinical manifestations and diagnosis of West Nile virus infection. Retrieved from https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-west-nile-virus-infection?search=plaque%20reduction%20neutralization%20test&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H349221233

PHE. (2019). Zika virus: sample testing advice. Retrieved from <https://www.gov.uk/guidance/zika-virus-sample-testing-advice>

RCOG/RCM/PHE/HPS. (2019). Zika Virus Infection and Pregnancy. Retrieved from <https://www.rcog.org.uk/globalassets/documents/guidelines/zika-virus-rcog-feb-2019.pdf>

Reynolds, M. R., Jones, A. M., Petersen, E. E., Lee, E. H., Rice, M. E., Bingham, A., . . . Honein, M. A. (2017). Vital Signs: Update on Zika Virus-Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure - U.S. Zika Pregnancy Registry, 2016. *MMWR Morb Mortal Wkly Rep*, 66(13), 366-373. doi:10.15585/mmwr.mm6613e1

Ricotta, V., Yu, Y., Clayton, N., Chuang, Y. C., Wang, Y., Mueller, S., . . . Rafailovich, M. (2019). A chip-based potentiometric sensor for a Zika virus diagnostic using 3D surface molecular imprinting. *Analyst*, 144(14), 4266-4280. doi:10.1039/c9an00580c

Robinson, J. L. (2017). Zika virus: What does a physician caring for children in Canada need to know? *Paediatr Child Health*, 22(1), 48-55. doi:10.1093/pch/pxx012

Shiu, C., Starker, R., Kwal, J., Bartlett, M., Crane, A., Greissman, S., . . . Curry, C. L. (2018). Zika Virus Testing and Outcomes during Pregnancy, Florida, USA, 2016. *Emerg Infect Dis*, 24(1), 1-8. doi:10.3201/eid2401.170979

St George, K., Sohi, I. S., Dufort, E. M., Dean, A. B., White, J. L., Limberger, R., . . . Zucker, H. A. (2017). Zika Virus Testing Considerations: Lessons Learned from the First 80 Real-Time Reverse Transcription-PCR-Positive Cases Diagnosed in New York State. *J Clin Microbiol*, 55(2), 535-544. doi:10.1128/jcm.01232-16

Voermans, J. J. C., Pas, S. D., van der Linden, A., GeurtsvanKessel, C., Koopmans, M., van der Eijk, A., & Reusken, C. (2019). Whole-Blood Testing for Diagnosis of Acute Zika Virus Infections in Routine Diagnostic Setting. *Emerg Infect Dis*, 25(7), 1394-1396. doi:10.3201/eid2507.182000

WHO. (2016a). Algorithm for detecting Zika virus (ZIKV). Retrieved from <https://www.paho.org/hq/dmdocuments/2016/2015-cha-algorithm-detecting-zikv.pdf>

WHO. (2016b). Laboratory testing for Zika virus infection. Retrieved from https://apps.who.int/iris/bitstream/handle/10665/204671/WHO_ZIKV_LAB_16.1_eng.pdf?sequence=1

WHO. (2016c). Pregnancy management in the context of Zika virus infection. Retrieved from https://apps.who.int/iris/bitstream/handle/10665/204520/WHO_ZIKV_MOC_16.2_eng.pdf?sequence=1

WHO. (2016d). WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. Retrieved from [https://www.who.int/en/news-room/detail/01-02-2016-who-statement-on-the-first-meeting-of-the-international-health-regulations-\(2005\)-\(ihr-2005\)-emergency-committee-on-zika-virus-and-observed-increase-in-neurological-disorders-and-neonatal-malformations](https://www.who.int/en/news-room/detail/01-02-2016-who-statement-on-the-first-meeting-of-the-international-health-regulations-(2005)-(ihr-2005)-emergency-committee-on-zika-virus-and-observed-increase-in-neurological-disorders-and-neonatal-malformations)

Policy Update History:

5/1/2022	New policy
----------	------------